Evidence map›Paper›PMID 36601043›Full record

ArticleEuropean urology open science2023

Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis.

Fady Ghali, Yibai Zhao, Devin Patel, Teresa Jewell, Evan Y Yu, Petros Grivas, R Bruce Montgomery, John L Gore, Ruth B Etzioni, Jonathan L Wright

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology open science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Fady GhaliDepartment of Urology, University of Washington School of Medicine, Seattle, WA, USA.
Yibai ZhaoBiostatistics Program, Fred Hutch Cancer Center, Seattle, WA, USA.
Devin PatelThe Urology Clinic of Colorado, Denver, CO, USA.
Teresa JewellLibrary Services, University of Washington School of Medicine, Seattle, WA, USA.
Evan Y YuDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Petros GrivasDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
R Bruce MontgomeryDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
John L GoreDepartment of Urology, University of Washington School of Medicine, Seattle, WA, USA.
Ruth B EtzioniBiostatistics Program, Fred Hutch Cancer Center, Seattle, WA, USA.
Jonathan L WrightDepartment of Urology, University of Washington School of Medicine, Seattle, WA, USA.
University of Washington · USFred Hutch Cancer Center · USThe Urology Center of Colorado · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Surrogate endpoints (SEs), such as progression-free survival (PFS) and objective response rate (ORR), are frequently used in clinical trials. The relationship between SEs and overall survival (OS) has not been well described in metastatic urothelial cancer (MUC). Objective: We evaluated trial-level data to assess the relationship between SEs and OS. We hypothesize a moderate surrogacy relationship between both PFS and ORR with OS. Design setting and participants: We systematically reviewed phase 2/3 trials in MUC with two or more treatment arms, and report PFS and/or ORR, and OS. Outcome measurements and statistical analysis: Linear regression was performed, and the coefficient of determination (R Results and limitations: Of 3791 search results, 59 trials and 62 comparisons met the inclusion criteria. Of the 53 trials that reported PFS, 31 (58%) reported proportional hazard regression for PFS and OS. Linear regression across trials demonstrated an R Conclusions: PFS provides only a moderate level of surrogacy for OS; An HR Patient summary: We examined the relationship between surrogate endpoints, common outcomes in clinical trials, with survival in urothelial cancer trials. Progression-free survival is moderately correlated, while objective response rate had a poor correlation with survival and should be de-emphasized as a primary endpoint.

Indexed as

Bladder cancerClinical trialsSurrogate endpoints

Identifiers

PMID36601043
PMCPMC9806712
OpenAlexW4311531799

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.